论文部分内容阅读
在接受降压治疗的高危高血压患者中观察诊间血压变异性(office blood pressure variability,OBPV)与心血管事件和死亡关系的研究不多。该研究对收缩压干预试验(systolic blood pressure intervention trial,SPRINT)进行事后分析,SPRINT试验将参与者随机分为强化降压组(目标血压<120mm Hg,1mm Hg=0.133kPa)或者标准降压组(目标血压<140mm Hg)。OBPV定义为在3,6,9和12个月的随访中测量的收
There is little research on the relationship between office blood pressure variability (OBPV) and cardiovascular events and death in hypertensive patients undergoing antihypertensive therapy. The study performed post-hoc analyzes of the systolic blood pressure intervention trial (SPRINT), which randomized participants to intensive hypotension (target BP <120 mm Hg, 1 mm Hg = 0.133 kPa) or standard BP lowering (Target blood pressure <140 mm Hg). OBPV was defined as the measure of follow-up at 3, 6, 9 and 12 months